LATE BREAKING CLINICAL TRIAL (JCS 2015) : Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study)

DOI Web Site Web Site PubMed 被引用文献22件 参考文献12件 オープンアクセス
  • Nakamura Mashio
    Department of Cardiology and Nephrology, Mie University Graduate School of Medicine
  • Nishikawa Masakatsu
    Clinical Research Support Center, Mie University Hospital
  • Komuro Issei
    Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine
  • Kitajima Isao
    Department of Clinical Laboratory and Molecular Pathology, Graduate School of Medical and Pharmaceutical Science, University of Toyama
  • Uetsuka Yoshio
    Department of Health Service and Hospital Administration, Tokyo Women’s Medical University
  • Yamagami Takuji
    Department of Radiology, Kochi Medical School, Kochi University
  • Minamiguchi Hiroki
    Department of Radiology, Wakayama Medical University
  • Yoshimatsu Rika
    Department of Radiology, Kochi Medical School, Kochi University
  • Tanabe Kosuke
    Clinical Research, Development Japan, Pfizer Japan
  • Matsuoka Nobushige
    Clinical Statistics, Development Japan, Pfizer Japan
  • Kanmuri Kazuhiro
    Clinical Research, Development Japan, Pfizer Japan
  • Ogawa Hisao
    Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University National Cerebral and Cardiovascular Center

書誌事項

タイトル別名
  • Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study)

この論文をさがす

抄録

Background:Anticoagulation is recommended as standard of care for venous thromboembolism (VTE) (pulmonary embolism [PE]/deep vein thrombosis [DVT]), for which unfractionated heparin (UFH) and warfarin are used in Japan. In the multi-regional AMPLIFY study, a fixed-dose regimen of apixaban alone was non-inferior to conventional therapy for treatment of PE/DVT and was associated with significantly fewer bleeding events.Methods and Results:Japan phase 3 study (AMPLIFY-J), randomized, active-controlled, open-label study in Japanese subjects with acute PE/DVT, was designed based on AMPLIFY. Key objectives were to investigate safety and efficacy of apixaban in symptomatic PE/DVT subjects during 24-week treatment. UFH/warfarin was used as control treatment. Apixaban was initiated at 10 mg twice daily for 7 days, followed by 5 mg twice daily for 23 weeks. All endpoints and imaging for thrombotic burden were assessed by an event adjudication committee. Eighty subjects were randomized, 33 subjects (41.3%) were aged <65 years. Proportion of major/clinically relevant non-major bleeding was lower in apixaban (7.5%) compared with well-controlled UFH/warfarin (28.2%; median TTR, 70.1%). Recurrent VTE occurred in no subjects in apixaban and in 1 subject in UFH/warfarin. Thrombotic burden results were similar in both groups. Proportions of subjects with adverse events was generally similar in both groups.Conclusions:Apixaban was well-tolerated and had a favorable safety profile. No clinically important efficacy difference compared with UFH/warfarin was observed. (Circ J 2015; 79: 1230–1236)

収録刊行物

  • Circulation Journal

    Circulation Journal 79 (6), 1230-1236, 2015

    一般社団法人 日本循環器学会

被引用文献 (22)*注記

もっと見る

参考文献 (12)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ